Zoetis Inc - Class A

ZTS

$204.73

+29.0% (1 year change)

Market Cap

$97 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$141.02 - $210.10

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

50.82x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.95 (0.46%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $97 Billion
Enterprise Value $101 Billion
Dividend Yield $0.95 (0.46%)
1 Year Return +29.5%
52-Week High $210.10
52-Week Low $141.02
Beta 0.77
Outstanding Shares 474 Million
Avg 30 Day Volume 1.38 Million

Valuation

P/E Ratio 50.82
PEG 158.07
Earnings per Share $3.99
Price to Sales Ratio 14.62
Price to Book Ratio 22.75
Revenue to Enterprise Value 14.34
EBIT to Enterprise Value 40.27
Total Debt to Enterprise Value 0.07
Debt to Equity 1.65

Profitability

Revenue $7.01 Billion
Gross Profit $4.87 Billion
EBIT $2.5 Billion
Net Income $1.77 Billion
Profit Margin 25.3%
Quarterly Earnings Growth (YoY) +32.2%
Return on Equity 40.78%
Return on Assets 12.61%
Return on Invested Capital 20.85%

Zoetis Inc - Class A

Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and precision livestock farming. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2019, the company generated annual revenue of $6.3 billion with approximately 10,600 employees.

News

Veterinary Vaccines Market to Reach USD 16.13 Billion with 6% CAGR by 2028; Novel Development of Easy-to-feed Medications for Dogs to Spur Growth: Fortune Business Insights

Veterinary Vaccines Market to Reach USD 16.13 Billion with 6% CAGR by 2028; Novel Development of Easy-to-feed Medications for Dogs to Spur Growth: Fortune Business Insights

Top Players Covered in the Veterinary Vaccines Market Research Report are Elanco (Greenfield, U.S.), HIPRA (Girona, Spain), Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany), Vi...

Intrado Digital Media Intrado Digital Media, 3 days ago
Vaccine for ASF could be developed within three years

Vaccine for ASF could be developed within three years

Tim Bettington is Executive Vice President and President, U.S. Operations and Global Customer Experience with Zoetis. It could take up to three more years to develop an active solution, Bettington ...

Brownfield Ag News Brownfield Ag News, 4 days ago
BRD Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027 | Bayer HealthCare, Boehringer Ingelheim, Elanco, Merck, Zoetis, Bimeda

BRD Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027 | Bayer HealthCare, Boehringer Ingelheim, Elanco, Merck, Zoetis, Bimeda

The BRD Treatment Market provides analysis and insights relating to the many factors expected to be rife throughout the forecast amount whereas providing their impacts on the Markets growth. The in...

OpenPR OpenPR, 4 days ago